HHS: Providers should order antibody therapies directly from distributor

February 25, 2021

This post has been archived and contains information that may be out of date.

The Department of Health and Human Services (HHS) has announced that the monoclonal antibody therapy bamlanivimab and antibody cocktail casirivimab/imdevimab will no longer be allocated to health departments,  and that authorized health care providers should order directly from AmerisourceBergen Corporation (ABC), the drugs’ sole distributor. The products remain free of charge to requesting sites. The federal government will continue to monitor all direct orders, and retains the capacity to resume allocation of these and future therapies if needed.  Additional information and link for direct ordering is available here

Additionally, the California Department of Public Health (CDPH) reports that CA  currently has a sufficient supply of monoclonal antibodies for all providers who request them. Facilities who need more monoclonal product should contact their county’s Medical and Health Operational Area Coordinators (MHOACs), who can then facilitate re-allocation of existing supply.  Medical directors or other authorized prescribers at SNFs and PACE programs who contract with specialty pharmacies receiving state allocations can order monoclonal product. The pharmacy would prepare the product and send to the SNF or PACE program for infusion.